|
Risk Periods
|
Number of Hospitalisations
|
Person-Years
|
Adjusted age and study month only RR(95% CI)
|
Adjusted* RR(95% CI)
|
|---|
|
Baseline unexposed Period
|
|---|
|
Unexposed
|
3275
|
2660
|
1.00 (1.00 - 1.00)
|
1.00 (1.00 - 1.00)
|
|
Pre-exposure to a beta blocker for heart failure
|
|
6-8 weeks
|
18
|
22
|
1.37 (0.93 - 2.01)
|
1.29 (0.88 - 1.89)
|
|
4-6 weeks
|
52
|
23
|
3.74 (2.90 - 4.82)
|
3.47 (2.70 - 4.46)
|
|
2-4 weeks
|
87
|
24
|
5.85 (4.72 - 7.26)
|
4.97 (4.02 - 6.16)
|
|
1 day-2 weeks
|
255
|
25
|
15.98 (13.51 - 18.91)
|
12.72 (10.74 - 15.07)
|
|
Post-exposure to a beta blocker for heart failure
|
|
1 day-2 weeks
|
46
|
25
|
2.85 (2.18 - 3.72)
|
2.21 (1.70 - 2.88)
|
|
2-4 weeks
|
25
|
23
|
1.63 (1.16 - 2.29)
|
1.29 (0.92 - 1.80)
|
|
1-4 months
|
94
|
107
|
1.34 (1.08 - 1.67)
|
1.18 (0.94 - 1.47)
|
|
4-8 months
|
46
|
76
|
0.78 (0.58 - 1.04)
|
0.76 (0.57 - 1.02)
|
|
8-12 months
|
15
|
24
|
0.66 (0.42 - 1.05)
|
0.62 (0.39 - 0.99)
|
- *Adjusted for age at heart failure hospitalisation[8], study month and time-varying covariates which were assessed quarterly; co-morbidities using the Australian adaption of Rx-Risk-V[19], number of prescribers, admission into aged care and prescription of frusemide, ACE/A2RB, digoxin and aldosterone antagonists
